(Q35776635)

10 August 2017

title

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis (English)

1 reference

10 August 2017

0 references

6

William R Bishai

1 reference

10 August 2017

7

Jacques H Grosset

1 reference

10 August 2017

8

Eric L Nuermberger

1 reference

10 August 2017

Ian M Rosenthal

1

1 reference

10 August 2017

Kathy Williams

2

1 reference

10 August 2017

Sandeep Tyagi

3

1 reference

10 August 2017

Charles A Peloquin

4

1 reference

10 August 2017

Andrew A Vernon

5

1 reference

10 August 2017

language of work or name

English

0 references

publication date

30 March 2006

1 reference

American Journal of Respiratory and Critical Care Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

174

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

94-101

1 reference

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Adverse Effects of Rifampin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Rifampicin activity "in vitro" and in established tuberculosis in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Clinical Pharmacokinetics of Rifampicin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

12 July 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

Rifapentine for the treatment of tuberculosis: is it all it can be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1862756

Pharmacokinetics of oral and intravenous rifampicin during chronic administration

25 September 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-280OC

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

21 January 2018

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I

1 reference

12 December 2020

Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin

1 reference

12 December 2020

Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit

1 reference

12 December 2020

A nested case-control study on treatment-related risk factors for early relapse of tuberculosis

1 reference

12 December 2020

Once upon a time. . . improved intermittent therapy for tuberculosis--fact or fable?

1 reference

12 December 2020

What is the 'right' dose of rifampin?

1 reference

12 December 2020

1 reference

12 December 2020

10.1164/RCCM.200602-280OC

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference